Substituted fused heterocycles as c-Met tyrosine kinase inhibitors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 26, 2016
Grant Date -
May 16, 2013
app pub date -
Jul 14, 2011
filing date -
Jul 14, 2010
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
This invention relates to certain novel fused quinazoline derivatives (Formula I) as c-Met inhibitors which is shown as formula I, their synthesis and their use for treating a c-Met mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful inhibitors of c-Met, methods for producing such compounds and methods for treating as c-Met mediated disorder
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2011 Application Filing Year
- A61K Class
- 10915 Applications Filed
- 8360 Patents Issued To-Date
- 76.60 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 3 Citation Count
- A61K Class
- 38.16 % this patent is cited more than
- 9 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jul 26, 2027 |
